166 related articles for article (PubMed ID: 30244171)
1. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.
Liu G; Yu M; Wu B; Guo S; Huang X; Zhou F; Claret FX; Pan Y
Cell Signal; 2019 Jan; 53():39-48. PubMed ID: 30244171
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
4. Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):886-900. PubMed ID: 30282449
[TBL] [Abstract][Full Text] [Related]
5. Let-7d Inhibits Growth and Metastasis in Breast Cancer by Targeting Jab1/Cops5.
Wei Y; Liu G; Wu B; Yuan Y; Pan Y
Cell Physiol Biochem; 2018; 47(5):2126-2135. PubMed ID: 29975923
[TBL] [Abstract][Full Text] [Related]
6. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor 1 promoter-induced JAB1 overexpression enhances chemotherapeutic sensitivity of lung cancer cell line A549 in an anoxic environment.
Hu MD; Xu JC; Fan Y; Xie QC; Li Q; Zhou CX; Mao M; Yang Y
Asian Pac J Cancer Prev; 2012; 13(5):2115-20. PubMed ID: 22901179
[TBL] [Abstract][Full Text] [Related]
8. Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome.
Pandey P; Siddiqui MH; Behari A; Kapoor VK; Mishra K; Sayyed U; Tiwari RK; Shekh R; Bajpai P
Anticancer Agents Med Chem; 2019; 19(16):2019-2033. PubMed ID: 31345154
[TBL] [Abstract][Full Text] [Related]
9. JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.
Danielpour D; Purighalla S; Wang E; Zmina PM; Sarkar A; Zhou G
Biochem Biophys Res Commun; 2019 Oct; 518(2):374-380. PubMed ID: 31434609
[TBL] [Abstract][Full Text] [Related]
10. CtBP1 transactivates RAD51 and confers cisplatin resistance to breast cancer cells.
Deng Y; Guo W; Xu N; Li F; Li J
Mol Carcinog; 2020 May; 59(5):512-519. PubMed ID: 32124501
[TBL] [Abstract][Full Text] [Related]
11. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
[TBL] [Abstract][Full Text] [Related]
12. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
Samsa WE; Mamidi MK; Bashur LA; Elliott R; Miron A; Chen Y; Lee B; Greenfield EM; Chan R; Danielpour D; Zhou G
Oncogene; 2020 Jun; 39(23):4581-4591. PubMed ID: 32390003
[TBL] [Abstract][Full Text] [Related]
13. Jab1/Cops5: a promising target for cancer diagnosis and therapy.
Yuan C; Wang D; Liu G; Pan Y
Int J Clin Oncol; 2021 Jul; 26(7):1159-1169. PubMed ID: 34019195
[TBL] [Abstract][Full Text] [Related]
14. Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.
Zhou F; Pan Y; Wei Y; Zhang R; Bai G; Shen Q; Meng S; Le XF; Andreeff M; Claret FX
Clin Cancer Res; 2017 Aug; 23(15):4450-4461. PubMed ID: 28270496
[No Abstract] [Full Text] [Related]
15. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of c-Jun activation domain-binding protein-1 in cancer: A systematic review and meta-analysis.
Shi D; Mu S; Hu B; Zhang S; Liu J; Zhang Z; Shao Z
J Cell Mol Med; 2021 Mar; 25(6):2750-2763. PubMed ID: 33550701
[TBL] [Abstract][Full Text] [Related]
17. Jab1 promotes glioma cell proliferation by regulating Siah1/β-catenin pathway.
Zhu Y; Qiu Z; Zhang X; Qian F; Wang B; Wang L; Shi H; Yu R
J Neurooncol; 2017 Jan; 131(1):31-39. PubMed ID: 27640199
[TBL] [Abstract][Full Text] [Related]
18. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer.
Yang M; Li Y; Shen X; Ruan Y; Lu Y; Jin X; Song P; Guo Y; Zhang X; Qu H; Shao Y; Quan C
J Exp Clin Cancer Res; 2017 Nov; 36(1):157. PubMed ID: 29116019
[TBL] [Abstract][Full Text] [Related]
19. Targeting Jab1/CSN5 in nasopharyngeal carcinoma.
Pan Y; Claret FX
Cancer Lett; 2012 Dec; 326(2):155-60. PubMed ID: 22867945
[TBL] [Abstract][Full Text] [Related]
20. Elucidation of the Chemopreventive Role of Stigmasterol Against Jab1 in Gall Bladder Carcinoma.
Pandey P; Bajpai P; Siddiqui MH; Sayyed U; Tiwari R; Shekh R; Mishra K; Kapoor VK
Endocr Metab Immune Disord Drug Targets; 2019; 19(6):826-837. PubMed ID: 30727937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
